Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.1
4.9
Journals
IJMS
Special Issues
Molecular Research and New Therapy in Melanoma and Other Skin...
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Molecular Research and New Therapy in Melanoma and Other Skin Cancers: 2nd Edition

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 20 May 2025 | Viewed by 3488

Special Issue Editor

Dr. Rüdiger Greinert

E-Mail Website
Guest Editor
Department of Molecular and Cell Biology, Skin Cancer Center Buxtehude, 21614 Buxtehude, Germany
Interests: photocarcinogenesis; epigenetics; (skin-) cancer stem cells; biomarkers (miRNA); tumor microenvironment (exosomes)
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue is a continuation of our previous Special Issue, titled “Molecular Research and New Therapy in Melanoma and Other Skin Cancers”.

Although we are experiencing increasing success in skin cancer therapy (especially malignant melanoma) by using immune checkpoint inhibition (ICI-) mono as well as combined therapy, skin cancer is still the most frequent cancer in the white population, causing more than 60,000 melanoma-related deaths worldwide each year. The reasons for this are primary and secondary (acquired) resistance against modern ICI therapies, as well as missing information about basic molecular events that induce skin cancer and therapy resistance. Therefore, there is an urgent need to increase evidence-based knowledge in molecular oncology, personalized diagnostics, precision medicine, and predictive assays to find early diagnostic, progression, and predictive molecular biomarkers to monitor skin cancer. Topics that should be focused on in the future (in addition to others) include tumor heterogeneity, tumor-microenvironment interaction (e.g., via exosomes), skin cancer biomarkers, transcriptomics, proteomics, epigenomics, immunomodulation, and the use of high throughput technologies. The main feature of this Special Issue is to provide a recent overview of ongoing molecular research by top experts in skin cancer development and therapy.

Dr. Rüdiger Greinert
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • epigenetics
  • cancer stem cells
  • noncoding RNA (miRNA)
  • personalized diagnostic (medicine)
  • personalized medicine
  • DNA repair
  • skin cancer biomarker
  • skin cancer prevention
  • genomics
  • transcriptomics
  • immunomodulation
  • ctDNA
  • circulating tumor cells
  • liquid biopsy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

18 pages, 3606 KiB  
Article
Impact of Rab27 on Melanoma Cell Invasion and sEV Secretion
by Katarzyna Horodecka, Liliana Czernek, Łukasz Pęczek, Mariusz Gadzinowski and Magdalena Klink
Int. J. Mol. Sci. 2024, 25(22), 12433; https://doi.org/10.3390/ijms252212433 - 19 Nov 2024
Cited by 1 | Viewed by 1049
Abstract
The migratory and invasive capabilities of melanoma cells contribute to metastasis. Therefore, targeting the genes driving these processes can support melanoma therapy. Rab27A and Rab27B contribute to tumor formation progression in many types of cancer through various mechanisms, including the secretion of small [...] Read more.
The migratory and invasive capabilities of melanoma cells contribute to metastasis. Therefore, targeting the genes driving these processes can support melanoma therapy. Rab27A and Rab27B contribute to tumor formation progression in many types of cancer through various mechanisms, including the secretion of small extracellular vesicles (sEVs). We explored the role of these GTPases in melanoma cell functioning in three RAB27A knockout (KO) cell lines (A375, DMBC12, and SkMel28) and a double RAB27A/B KO A375 cell line. The loss of RAB27A impaired the migration and invasion of DMBC12 and SkMel28 cells; however, the behavior of highly aggressive A375 cells was unaffected. The RAB27A/B double knockout moderately decreased the migratory capacity of A375 cells without disturbing their invasiveness. Additionally, the silencing of RAB27A did not affect the number and mean size of the sEVs, despite some alterations in the protein content of the vesicles. Both Rab27 isoforms can, at least partially, act independently. The potential role of Rab27A in the functioning of melanoma cells depends on the individual character of the cell line, but not on its basal expression, and seems to be unrelated to the secretion of sEVs. Full article
(This article belongs to the Special Issue Molecular Research and New Therapy in Melanoma and Other Skin Cancers: 2nd Edition)
►▼ Show Figures

Figure 1

Review

Jump to: Research

26 pages, 409 KiB  
Review
Advancing Treatment Options for Merkel Cell Carcinoma: A Review of Tumor-Targeted Therapies
by Helena M. Nammour, Karla Madrigal, Caroline T. Starling and Hung Q. Doan
Int. J. Mol. Sci. 2024, 25(20), 11055; https://doi.org/10.3390/ijms252011055 - 15 Oct 2024
Cited by 2 | Viewed by 2012
Abstract
Although rare, Merkel cell carcinoma (MCC) is a highly aggressive and increasingly prevalent neuroendocrine cancer of the skin. While current interventions, including surgical resection, radiation, and immunotherapy have been employed in treating many patients, those who remain unresponsive to treatment are met with [...] Read more.
Although rare, Merkel cell carcinoma (MCC) is a highly aggressive and increasingly prevalent neuroendocrine cancer of the skin. While current interventions, including surgical resection, radiation, and immunotherapy have been employed in treating many patients, those who remain unresponsive to treatment are met with sparse alternatives and a grim prognosis. For this reason, it is of interest to expand the repertoire of available therapies for MCC patients who remain resistant to current primary interventions. Recently, our improved mechanistic understanding of aberrant cell signaling observed in both MCPyV-positive and -negative MCC has facilitated exploration into several small molecules and inhibitors, among them receptor tyrosine kinase inhibitors (TKIs) and somatostatin analogs (SSAs), both of which have positively improved response rates and reduced tumor volumes upon application to treatment of MCC. The introduction of such targeted therapies into treatment protocols holds promise for more personalized care tailored towards patients of diverse subtypes, thereby improving outcomes and mitigating tumor burden, especially for treatment-resistant individuals. In this review, we characterize recent findings surrounding targeted treatments that have been applied to MCC and provide an overview of emerging perspectives on translatable options that can be further developed to offer additional therapeutic avenues for patients with the disease. Full article
(This article belongs to the Special Issue Molecular Research and New Therapy in Melanoma and Other Skin Cancers: 2nd Edition)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop